Principal Investigators

    Prof Christopher Dobson

    Institution

    University of Cambridge

    Contact information of lead PI

    Country

    United Kingdom

    Title of project or programme

    Molecular Basis of Protein Misfolding Disorders.

    Source of funding information

    The Wellcome Trust

    Total sum awarded (Euro)

    € 1,560,915

    Start date of award

    27/06/2011

    Total duration of award in years

    6.0

    The project/programme is most relevant to:

    Neurodegenerative disease in general

    Keywords

    Research Abstract

    Our programme concerns the identification of the molecular basis of protein misfolding disorders. We will build on the generic view of protein aggregation to investigate five major questions: Objective 1: Kinetics of Protein Aggregation To define the microscopic processes underlying the phenomenon of protein aggregation, and the factors that determine their initiation and their rates. Objective 2: Thermodynamics of Protein Aggregation To analyse the thermodynamic stabilities of the diffe rent states of proteins, and their links with the roles of kinetic factors in enabling them to remain functional in crowded cellular environments. Objective 3: Metastability of the Human Proteome To characterise the origins of pathogenesis in misfolding diseases in terms of the interaction between amyloid species and the set of human proteins that are metastable against aggregation. Objective 4: Biological Regulation of Protein Aggregation To analyse the mechanisms by which chaperones and other biological processes protect against protein aggregation in vivo, and how these pathways depend on risk factors ranging from mutagenesis to ageing. Objective 5: Chemical Regulation of Protein Aggregation To develop principles and methods of rational intervention in misfolding diseases, including potential therapies, based on the knowledge of the specific mechanisms of aggregation and on the restoration of the health of the proteome as a whole.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: United Kingdom
Diseases: Neurodegenerative disease in general
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF